Executive Management

 

   
  Martin Olin, EMBA, M.Sc.
Chief Executive Officer
Before joining Symphogen, Mr. Olin served as Senior Investment Manager at Scandinavian Life Science Invest (SLS Invest). Prior to his position with SLS Invest, Olin was the Finance Director, EMEA for Novo Nordisk managing finance, IT and customer service for the region. Mr. Olin has more than a decade of executive experience with life science companies and has been involved in numerous private equity transactions, trade sales and commercial partnerships. Mr. Olin serves as director on the board of several life science companies in the US and in Europe.
   
     
Ivan D. Horak, MD, FACP
Head of Global R&D, Chief Scientific and Medical Officer
Prior to joining Symphogen, Dr. Horak served as President of Research and Development and Chief Scientific Officer of Enzon Pharmaceuticals Inc. Before that, Dr. Horak served as Chief Scientific Officer of Immunomedics, responsible for development of novel antibodies. Dr. Horak has authored over 70 peer-reviewed publications and several book chapters within the fields of hematology, oncology, and immunology and has served on the editorial boards of several scientific journals. Dr. Horak is board certified oncologist. He is Fellow of American College of Physicians and member of American Association for Cancer Research, American Society of Hematology, and American Society Clinical Oncology.
 
     
     
Mads Laustsen, M.Sc.

Chief Manufacturing Officer
Mr. Laustsen has more than 25 years of international experience within biologics development and manufacturing from CMC Biologics, Novozymes, Zymogenetics and Novo. Laustsen co-founded CMC Biologics where he was the Chief Executive Officer and Chief Science Officer prior to joining Symphogen.
Mr. Laustsen is a Board of Directors member of CMC Biologics, holds numerous patents related to biologics manufacturing, and is on the Advisory Board of Institute of System Biology at the Danish Technical University.

 
     
     
Jesper Bramming, M.Sc. Economics

Chief Financial Officer
Prior to joining Symphogen, Mr. Bramming comes from the CMC Biologics Group where he was Chief Financial Officer and a member of the Group Management Team. His responsibilities included financial accounting and reporting, legal, IT and Board management for the US and Copenhagen offices. Before joining CMC Biologics, Mr. Bramming was with Nets Holding A/S where he also held the position of Chief Financial Officer and Executive Vice President. Prior to that, for sixteen years, he ran the financial groups of Both A.P. M├śller-Maersk and Maersk Oil & Gas. Prior to these assignments, Bramming held a number of top positions in banking and investment management in leading European firms. He holds Board seats as Chairman of both Menu A/s/Scandinavia Living A/S and Rejsekort A/S, and is a director of Danske Invest Management. He holds a Master of Economics from the University of Copenhagen, and is an alumni of Columbia University's Senior Executive Management Program. He is also a Chartered Financial Analyst.